Submental Fat Clinical Trial
Official title:
A Double Blind, Randomized, Three Arm, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of RZL-012 in Subjects Seeking for Submental Fat Reduction
A total of 135 eligible male or female subjects will be randomized according to a predetermined randomization scheme (1:1:1 ratio) to receive a single multi-injection treatment of high dose RZL-012, low dose RZL-012, or placebo on Day 0. They will be monitored for safety and efficacy over 84 days.
Each subject will be randomized to either active treatment (high or low dose RZL-012) or placebo at a ratio of 1:1:1 per group and receive one of the following: - low dose (concentration of injected solution 34 mg/mL RZL-012) of 5.1 mg/0.15 mL/injection point that results in a dose/volume of 163.2±20.4 mg/4.8±0.6 mL RZL-012, - high dose (concentration of injected solution 50 mg/mL RZL-012) of 7.5 mg/0.15 mL/injection point that results in a maximum total dose/volume of 240±30 mg/4.8±0.6 mL RZL-012, - placebo of 0.15 mL/injection point that results in a total maximum volume of 4.8±0.6 mL. Subjects treated with RZL-012 will undergo a single treatment session with 32±4 injections. The maximal number of injections will be 36 with maximal doses of 183.6 mg and 270 mg for the low and high doses, respectively. Each injection point will be dosed with 5.1 mg RZL-012 for the low dose or 7.5 mg for the high dose in a volume of 0.15 mL/injection site. Placebo (vehicle) subjects will be injected with a 0.15 mL vehicle per each injection site. The maximal injection volume for all groups will be up to 5.4 mL. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05476679 -
Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events
|
Phase 1/Phase 2 | |
| Completed |
NCT04144049 -
A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat
|
Phase 2 | |
| Active, not recruiting |
NCT05154955 -
A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat
|
Phase 2 | |
| Completed |
NCT04258761 -
A Safety and Tolerability Study of 10XB-101 Injections in Adult Subjects With Extra Fat Under the Chin ("Double Chin")
|
Phase 2 | |
| Completed |
NCT05763160 -
An Open-label Study That Will Test a Second Treatment Session of RZL-012.
|
Phase 2 | |
| Completed |
NCT03946592 -
Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat
|
Phase 3 | |
| Completed |
NCT05466448 -
An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese vs. Non-Chinese Subjects.
|
Phase 1/Phase 2 | |
| Completed |
NCT04086823 -
A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.
|
Phase 2 | |
| Completed |
NCT02159729 -
Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
|
Phase 2 | |
| Completed |
NCT05195112 -
Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat
|
Phase 3 | |
| Completed |
NCT03005717 -
Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat
|
Phase 2 | |
| Completed |
NCT02163902 -
Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
|
Phase 3 | |
| Completed |
NCT05476094 -
Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects
|
Phase 1 |